Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Jul 14, 2020
DUPIXENT® (dupilumab) receives positive recommendation from INESSS for the treatment of moderate-to-severe atopic dermatitis in adolescents
Jul 8, 2020
SARCLISA™ (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
Jun 17, 2020
Sanofi: Important Information on Plaquenil® and COVID-19
Apr 24, 2020
DUPIXENT® (dupilumab) receives positive recommendation from CADTH for moderate-to-severe atopic dermatitis
Apr 14, 2020
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Apr 2, 2020
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 2, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Jan 30, 2020
Sanofi Canada named a Top Employer in Montreal for 2020, the third similar recognition in the last six months
Nov 22, 2019
Sanofi Canada named one of Canada's Top 100 Employers for 2020
Oct 22, 2019
Patients in Quebec now have access to DUPIXENT™ for the treatment of moderate-to-severe atopic dermatitis
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
10
11
»
